Presentation

At NeoVentures Biotechnology Europe, we revolutionize biomarker-based approaches. Our next-gen proteomics platform, using reproducible DNA aptamer libraries, analyzes molecular profiles in plasma and liquid biopsies to validate cancer or relapse biomarkers Leveraging advanced aptamer libraries and machine learning, we screen 16.8 million interactions to reveal molecular complexities, focusing on providing reliable solutions for predictive diagnostics and prognostics.

Contact

Gregory PENNER, CEO, info@neoventures-eu.com

Website
http://neoventures-eu.com/